Sugi Predict

Sugi Predict / Compounds / SCHEMBL19948826

SCHEMBL19948826

SCHEMBL19948826

CSc1nc2c(c(N3CCN(C(=O)OC(C)(C)C)[C@@H](CC#N)C3)n1)CCN(C(=O)OCc1ccccc1)C2

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 1/20 0.45
▸ NR1H2 P55055 2/20 0.39
▸ NR1H3 Q13133 2/20 0.39
▸ TMEM97 Q5BJF2 4/20 0.39
▸ SIGMAR1 Q99720 4/20 0.39
▸ KRAS P01116 10/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ IDH1 O75874 1/20 0.38
▸ CXCR3 P49682 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19947663 0.97 PARP1 (0.41) PARP1NR1H2NR1H3TMEM97SIGMAR1
SCHEMBL19947785 0.97 PARP1 (0.41) PARP1NR1H2NR1H3TMEM97SIGMAR1
SCHEMBL23668496 0.93 PARP1 (0.44) PARP1NR1H2NR1H3TMEM97SIGMAR1
SCHEMBL19949087 0.91 IDH1 (0.41) TMEM97SIGMAR1KRASIDH1
SCHEMBL19949089 0.91 IDH1 (0.41) TMEM97SIGMAR1KRASIDH1
SCHEMBL19948615 0.90 PARP1 (0.46) PARP1NR1H2NR1H3TMEM97SIGMAR1
SCHEMBL19964057 0.89 MTOR (0.36) PARP1TMEM97SIGMAR1KRASMEN1
SCHEMBL21315017 0.88 KRAS (0.37) NR1H2NR1H3KRAS
SCHEMBL21315015 0.88 KRAS (0.37) NR1H2NR1H3KRAS
SCHEMBL20974822 0.88 PARP1 (0.44) PARP1NR1H2NR1H3TMEM97SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4501932-A2 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2025-02-05 — — EP disclosed
EP-3880208-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-11-20 — — EP disclosed
CN-111989321-B KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2024-05-14 — — CN disclosed
US-20240101553-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-03-28 — — US disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 — — US disclosed
CN-116675690-A Preparation method of lung cancer treatment medicine 北京康立生医药技术开发有限公司 2023-09-01 — — CN disclosed
CN-116194456-A Preparation of heterocyclic compounds as KRAS inhibitors and methods of use thereof 上海科州药物研发有限公司 2023-05-30 — — CN disclosed
EP-3710439-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-02-15 — — EP disclosed
EP-3880208-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2021-09-22 — — EP disclosed
US-20200308170-A1 KRAS G12C INHIBITORS ARRAY BIOPHARMA INC. 2020-10-01 — — US disclosed
WO-2020101736-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2020-05-22 — — WO disclosed
US-10647715-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2020-05-12 — — US disclosed
US-10647715-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2020-05-12 — — US disclosed
US-10633381-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2020-04-28 — — US disclosed
US-20190270743-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2019-09-05 — — US disclosed
US-20190270743-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2019-09-05 — — US disclosed
US-20190144444-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2019-05-16 — — US disclosed
US-20190144444-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2019-05-16 — — US disclosed
US-10125134-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2018-11-13 — — US disclosed
US-20180072723-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2018-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190144444-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS PARP1 1128/4885NR1H2 1539/4885NR1H3 1479/4885
US-10633381-B2 KRas G12C inhibitors KRAS, NRAS, HRAS PARP1 1128/4885NR1H2 1539/4885NR1H3 1479/4885
US-10647715-B2 KRas G12C inhibitors KRAS, NRAS, HRAS PARP1 1128/4885NR1H2 1539/4885NR1H3 1479/4885
US-10125134-B2 KRas G12C inhibitors KRAS, NRAS, HRAS PARP1 1128/4885NR1H2 1539/4885NR1H3 1479/4885
US-20200308170-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS PARP1 1128/4885NR1H2 1539/4885NR1H3 1479/4885
US-20240101553-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS PARP1 1128/4885NR1H2 1539/4885NR1H3 1479/4885
US-20190270743-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS PARP1 1128/4885NR1H2 1539/4885NR1H3 1479/4885
US-20180072723-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS PARP1 1128/4885NR1H2 1539/4885NR1H3 1479/4885
US-20230373999-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS PARP1 1128/4885NR1H2 1539/4885NR1H3 1479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.